Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

UNITED THERAPEUTICS (UTHR) Liabilities and Shareholders Equity: 2009-2025

Historic Liabilities and Shareholders Equity for UNITED THERAPEUTICS (UTHR) over the last 16 years, with Sep 2025 value amounting to $7.4 billion.

  • UNITED THERAPEUTICS's Liabilities and Shareholders Equity rose 3.20% to $7.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $30.4 billion, marking a year-over-year increase of 10.39%. This contributed to the annual value of $7.4 billion for FY2024, which is 2.75% up from last year.
  • UNITED THERAPEUTICS's Liabilities and Shareholders Equity amounted to $7.4 billion in Q3 2025, which was down 7.04% from $7.9 billion recorded in Q2 2025.
  • UNITED THERAPEUTICS's 5-year Liabilities and Shareholders Equity high stood at $7.9 billion for Q2 2025, and its period low was $4.6 billion during Q1 2021.
  • In the last 3 years, UNITED THERAPEUTICS's Liabilities and Shareholders Equity had a median value of $7.1 billion in 2024 and averaged $7.1 billion.
  • Data for UNITED THERAPEUTICS's Liabilities and Shareholders Equity shows a peak YoY rose of 21.48% (in 2023) over the last 5 years.
  • UNITED THERAPEUTICS's Liabilities and Shareholders Equity (Quarterly) stood at $5.2 billion in 2021, then increased by 16.94% to $6.0 billion in 2022, then climbed by 18.57% to $7.2 billion in 2023, then increased by 2.75% to $7.4 billion in 2024, then climbed by 3.20% to $7.4 billion in 2025.
  • Its last three reported values are $7.4 billion in Q3 2025, $7.9 billion for Q2 2025, and $7.7 billion during Q1 2025.